by Maria Zannes | Oct 22, 2017 | Events
bioAffinity Technologies’ CEO, Maria Zannes, will lead a panel of leaders from UT Health, UTSA and the City of San Antonio to discuss how the Company has grown in San Antonio and how others can benefit from their story. Thursday, November 9 at noon at the San...
by Maria Zannes | Aug 24, 2017 | News
Texas Public Radio To listen to the story, click here. AUGUST 24, 2017 By Wendy Rigby, Bioscience and Medicine Reporter A new, more accurate, test for lung cancer is being developed in San Antonio. It’s a screening that could help save the lives of...
by Maria Zannes | Jul 27, 2017 | News
uly 27, 2017 As published in the San Antonio Express-News. by Jesse Pound San Antonio-based biotech company bioAffinity raised over $4 million as it plans to bring its new lung cancer test to market next year, according to securities filings. The funding round, which...
by Maria Zannes | May 23, 2017 | Events
May 23, 2017 @ 11:30 am-1:00 pm Online registration is now open and the RSVP deadline is Fri. May 19th. ACG Member price: $30./Non-ACG Member price: $55. until the RSVP deadline. Prices increase $10 each after the RSVP deadline. Maria Zannes brings more than 30...
by Maria Zannes | May 3, 2017 | Press Releases
MAY 3, 2017 (SAN ANTONIO, TX ) bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030. The EPO patent, titled “System...
